Knowledge, attitudes and practices among people with chronic hepatitis B attending a hepatology clinic in Malaysia: a

Rosmawati Mohamed1, Chirk Jenn Ng, Wen Ting Tong

  • 1Department of Medicine, Faculty of Medicine, University of Malaya, Malaya 50603, Kuala Lumpur, Malaysia. ros@ummc.edu.my

BMC Public Health
|August 4, 2012
PubMed

Insights

Hepatitis B patients exhibit significant knowledge gaps and persistent stigma, particularly concerning transmission and social disclosure. Enhanced patient and public education are crucial for improving awareness and reducing misconceptions about chronic Hepatitis B infection.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis B virus (HBV) infection is a primary global cause of liver cirrhosis and hepatocellular carcinoma.
  • Understanding the knowledge, attitudes, and practices of individuals with chronic HBV is critical for effective management.

Purpose of the Study:

  • To assess the knowledge, attitudes, and practices of patients with chronic Hepatitis B.
  • To identify factors associated with these knowledge, attitudes, and practices.

Main Methods:

  • A cross-sectional study was conducted at a tertiary hospital's adult hepatology clinic.
  • Self-administered questionnaires were used to gather data on knowledge, attitudes, and lifestyle practices.

Main Results:

  • Participants aged 30-39, with higher education, professional jobs, longer diagnosis duration, and no cirrhosis showed higher knowledge scores.
  • Over half worried about transmission; a third felt embarrassed to disclose their diagnosis, though most informed family.
  • Half avoided sharing utensils, believing HBV is transmitted via shared dining ware; older patients were less likely to share.

Conclusions:

  • Significant stigma and misconceptions persist among Hepatitis B patients.
  • There is a need for increased patient and public education on HBV transmission and prevention.
  • Educational initiatives are essential to raise awareness and demystify Hepatitis B.
Abstract

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...